Chaplain G, Cuisenier J, Milan C, Smail M, Janoray P, Collin F, Déchelotte D, Michiels-Marzais D, Jahier J, Michiels R
Registre bourguignon de pathologie gynécologique, Dijon, France.
Bull Cancer. 1994 Aug;81(8):691-7.
In the French administrative "departement" of Côte-d'Or, between 1982 and 1990, the crude incidence rate and the age-adjusted world standardised incidence rate (ASR) for corpus uteri cancer were respectively 16.0 +/- 0.8 and 10.7 +/- 0.6 per 100,000 women per year. The incidence increased after 50 years of age, reaching a maximum of 66.7 per 100,000 women per year at the age of 70-74 and thereafter declined. Ninety-six percent of the patients were older than 50. The 5- and 10-year crude survival rates (all histologic types) were 66 +/- 3% and 61 +/- 4%. The 5- and 10-year relative survival rates were 76%. Histologic types were specified in 99.7% of cases, categorized as follows: 92.7% carcinomas (333 cases), 6.7% sarcomas (24 cases) and 0.3% lymphoma (one case). Carcinomas were clinically evaluated according to FIGO staging: stage I: 61.4% (205 cases); stage II: 7.7% (59 cases); stage III: 7.8% (26 cases); stage IV: 6.6% (22 cases) and unspecified stage: 6.6% (22 cases). The ASR by stage, were 6.4 +/- 0.5 (stage I); 0.8 +/- 0.2 (stage II); 1.3 +/- 0.2 (stages III and IV); 0.6 +/- 0.2 (unspecified stage). The 5-year relative survival rates related to FIGO stage were 90% (stage I); 85% (stage II); 25% (stage III) and 0% (stage IV). Elderly patients (> 75) had significantly lower survival rates. With respect to localized disease (stages I and II) the relative risk of death associated with age older than 75 was 4.9. The 5-year relative survival rate of patients with sarcoma was 37%.
在法国科多尔省行政区，1982年至1990年间，子宫体癌的粗发病率和年龄调整后的世界标准化发病率（ASR）分别为每年每10万名女性16.0±0.8和10.7±0.6。发病率在50岁以后上升，在70 - 74岁时达到每年每10万名女性66.7的最高值，此后下降。96%的患者年龄超过50岁。5年和10年的粗生存率（所有组织学类型）分别为66±3%和61±4%。5年和10年的相对生存率为76%。99.7%的病例明确了组织学类型，分类如下：92.7%为癌（333例），6.7%为肉瘤（24例），0.3%为淋巴瘤（1例）。癌根据国际妇产科联盟（FIGO）分期进行临床评估：I期：61.4%（205例）；II期：7.7%（59例）；III期：7.8%（26例）；IV期：6.6%（22例）；分期未明：6.6%（22例）。各期的ASR分别为：6.4±0.5（I期）；0.8±0.2（II期）；1.3±0.2（III期和IV期）；0.6±0.2（分期未明）。与FIGO分期相关的5年相对生存率分别为：90%（I期）；85%（II期）；25%（III期）和0%（IV期）。老年患者（>75岁）的生存率显著较低。对于局限性疾病（I期和II期），75岁以上患者的死亡相对风险为4.9。肉瘤患者的5年相对生存率为37%。
